Journal Mobile Options
Table of Contents
Vol. 115, No. 3-4, 2006
Issue release date: March 2006
Section title: Paper
Acta Haematol 2006;115:192–197
(DOI:10.1159/000090934)

3′ End Processing of the Prothrombin mRNA in Thrombophilia

Danckwardt S. · Hartmann K. · Gehring N.H. · Hentze M.W. · Kulozik A.E.
aDepartment of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, bEMBL – University of Heidelberg Molecular Medicine Partnership Unit, cEuropean Molecular Biology Laboratory, Heidelberg, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 3/17/2006

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 0

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: http://www.karger.com/AHA

Abstract

Clinical and genetic studies have led to the discovery of specific genotypes that predispose to thromboembolism in adults and children. The exploration of the underlying pathologies has revealed a broad variety of affected molecular mechanisms. Most recently, the functional analysis of the prothrombin (F2) 20210*A variant revealed increased efficiency of 3′ end processing as a novel genetic mechanism predisposing to human disease. Here, we review the 3′ end processing of the human F2 mRNA and demonstrate how clinically relevant mutations in the F2 gene contribute to thrombophilia by interfering with a tightly balanced architecture of noncanonical 3′ end formation signals.


  

Author Contacts

Andreas E. Kulozik
Molecular Medicine Partnership Unit, Im Neuenheimer Feld 153
DE–69120 Heidelberg (Germany)
Tel. +49 6221 564555, Fax +49 6221 564559
E-Mail Andreas.Kulozik@med.uni-heidelberg.de

  

Article Information

Number of Print Pages : 6
Number of Figures : 3, Number of Tables : 0, Number of References : 47

  

Publication Details

Acta Haematologica

Vol. 115, No. 3-4, Year 2006 (Cover Date: March 2006)

Journal Editor: Ben-Bassat, I. (Tel Hashomer)
ISSN: 0001–5792 (print), 1421–9662 (Online)

For additional information: http://www.karger.com/AHA


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 3/17/2006

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 0

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: http://www.karger.com/AHA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.